Get my own profile
Public access
View all27 articles
9 articles
available
not available
Based on funding mandates
Co-authors
- Darren McKerrecherAstraZenecaVerified email at astrazeneca.com
- Graeme RobbDirector, AstraZenecaVerified email at astrazeneca.com
- Richard A WardAstraZenecaVerified email at astrazeneca.com
- Paul LeesonPaul Leeson Consulting LtdVerified email at nottingham.ac.uk
- David AndrewsAstraZenecaVerified email at astrazeneca.com
- Andrew LeachHead of Chemical Biology, European Bioinformatics InstituteVerified email at ebi.ac.uk
- Martin NobleProfessor of Structural Biology and Anticancer Drug DesignVerified email at ncl.ac.uk
- Jessica GrahamNewcastle UniversityVerified email at newcastle.ac.uk
- Duncan C MillerNewcastle UniversityVerified email at ncl.ac.uk
- Martin SwarbrickDirector R&D Chemistry, Ryvu Therapeutics SAVerified email at ryvu.com
- Celine CanoNewcastle universityVerified email at ncl.ac.uk
- Claudio ChuaquiSyros PharmaceuticalsVerified email at syros.com
- Cath EberleinBiVictriX Therapeutics Ltd.Verified email at bivictrix.com
- Cameron AlexanderSchool of Pharmacy, University of NottinghamVerified email at nottingham.ac.uk
- Marianne AshfordAstraZenecaVerified email at astrazeneca.com
- Richard Mark EnglandAssociate Director, AstraZeneca PLC UKVerified email at astrazeneca.com
- Gary WilkinsonDirector Clinical Pharmacology, Bayer, GermanyVerified email at bayer.com
- Stephen J HillUniversity of NottinghamVerified email at nottingham.ac.uk
- Joe PatelC4 TherapeuticsVerified email at c4therapeutics.com
- Huawei Ray ChenZentaur TherapeuticsVerified email at Zentaurtx.com